FREE SHIPPING ON ORDERS OVER $150

what makes glutathione s transferase transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases Phase II - Glutathione Conjugation

$29.53

Quantity
- +
Description

Common treatments for OA include non-pharmacological, pharmacological (non-steroidal anti-inflammatory drugs (NSAIDs) and intra-articular injections), and surgical interventions [1, 4]

what makes glutathione s transferase transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases Phase II - Glutathione Conjugation

Together were included: control animals (rats without any surgical intervention, decapitated under anaesthesia) n = 7, rats with ischemia/reperfusion: 3 h n = 5, 24 h n = 7, 72 h n = 5, rats with ischemic preconditioning and ischemia/reperfusion: 3 h n = 5, 24 h n = 7, 72 h n = 5

what makes glutathione s transferase transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases Phase II - Glutathione Conjugation

It has been safely used in a number of preclinical and clinical trials

what makes glutathione s transferase transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases Phase II - Glutathione Conjugation

Tjalkens RB, Cook LW, Petersen DR

what makes glutathione s transferase transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases Phase II - Glutathione Conjugation

It also attenuates the metabolic reprogramming of cancer cells (Figure 2)

what makes glutathione s transferase transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases Phase II - Glutathione Conjugation

2017 Jun 20;46(6):1089-1090)

what makes glutathione s transferase transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases Phase II - Glutathione Conjugation

You may also like

recommand products